Navigation Links
Breckenridge Announces Approval of Generic Activella® 0.5mg/0.1mg Tablets
Date:6/10/2011

BOCA RATON, Fla., June 10, 2011 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Activella® 0.5mg/0.1mg Tablets. The company currently markets an equivalent to Activella® 1.0mg/0.5mg Tablets, as (Estradiol/Norethindrone Acetate 1.0mg/0.5mg) Tablets.

Estradiol/Norethindrone Acetate Tablets is AB rated to Activella®, a brand product marketed by Novo Nordisk®, which is used as a treatment for moderate to severe vasomotor symptoms associated with menopause, and as prevention for postmenopausal osteoporosis. The original dose strength is also indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause in women who have a uterus.

The brand product had trailing 12 month sales of $28.5 million, based on industry sales data.

Breckenridge products are manufactured through partnerships with pharmaceutical manufacturers in state-of-the-art facilities throughout the world. Breckenridge maintains a stringent Quality Assurance program to ensure a consistent supply of quality pharmaceutical products.

About Breckenridge:

Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions, and Powders. www.bpirx.com


'/>"/>
SOURCE Breckenridge Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Breckenridge Announces Approval of Anastrozole Tablets
2. Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ)
3. Breckenridge Pharmaceutical Enters Agreement with Oman Pharmaceutical Products Company LLC
4. Breckenridge Pharmaceutical Announces Settlement of Actos® (Pioglitazone Hydrochloride) Patent Litigation
5. Breckenridge Announces Approval of Letrozole Tablets
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ), the leader in ... at the BMO Capital Markets Prescriptions for Success Healthcare Conference on ... A live webcast of the presentation will be available ... replay will be available within 48 hours and will be archived ... , ...
(Date:12/7/2016)... 2016 According to the latest ... Market Study on Multiplex Detection Immunoassay: North America to ... global multiplex detection immunoassay market is expected to witness a CAGR ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
(Date:12/7/2016)... 7, 2016 The global  ... value of USD 3.9 billion by 2024, based ... Inc. The growth of the market is attributed ... technological advancements by the market players. Demand for ... increasing donation, rising awareness about transfusion-transmitted diseases, and ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... ... consultation services to residents in the Sacramento/Folsom region, is initiating a charity event ... , The Another Choice Another Chance treatment center in Sacramento works to provide ...
(Date:12/7/2016)... NY (PRWEB) , ... December 07, 2016 , ... A. ... business owners and families throughout the Five Boroughs, is launching a charity drive to ... works to continue the traditions and spirit of marines and Navy FMF Corpsmen. Working ...
(Date:12/7/2016)... IL (PRWEB) , ... December 07, 2016 , ... Facial ... back this holiday season by donating a portion of proceeds to two local organizations: ... North Chicago Animal Control & Friends is a team of authorized and trained ...
(Date:12/7/2016)... Studio City, CA (PRWEB) , ... December 07, 2016 , ... ... number during the holidays and winter seasons. One major study analyzing heart attacks ... January compared to August of a given year. We would all agree of course–no ...
(Date:12/7/2016)... Norwalk, CT (PRWEB) , ... December 07, 2016 ... ... the Integrated Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut ... which now has a team of three acupuncturists to help patients realize their ...
Breaking Medicine News(10 mins):